Wockhardt Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 7 Aug 2026 | Market Cap: ₹32.6K Cr
Wockhardt aims to double its business in the next 3 years, driven by increased capacity and growing demand, especially in novel antibiotics and biosimilars. EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%.
From Wockhardt Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,886
Market Cap
₹32.6K Cr
P/E Ratio
114.8
Wockhardt Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹965 Cr, net profit ₹164 Cr.
Full financials →📊 Revenue & Sales Performance
- →Wockhardt aims to double its business in the next 3 years, driven by increased capacity and growing demand, especially in novel antibiotics and biosimilars.
- →The novel antibiotic ZAYNICH targets a global addressable market of about $9 billion with plans to scale in India and Western markets, including the US and Europe.
- →Miqnaf targets the Indian respiratory antibiotic market valued at INR10,800 crores with specialist-focused promotion over the next 3-4 years.
- →The diabetes biosimilar business, particularly insulin glargine and other analogs, represents a significant growth area in emerging markets and India, with new product launches planned.
- →Capacity expansion includes doubling insulin production facilities over 24 months to capitalize on opportunities from competitors scaling back.
- →Overall, multiple growth levers with a combination of product launches, market expansion, and operational efficiencies are expected to accelerate top-line growth and EBITDA margin improvement.
📈 Profitability & Margins
- →EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. This indicates strong profitability momentum.
- →Revenue outlook: Continued growth expected driven by novel antibiotic portfolio (ZAYNICH, Miqnaf, EMROK), diabetes biosimilar business (insulin glargine, Aspart), and emerging market expansion.
- →Research & Development: Annual R&D spend around USD 200-250 million aimed at pipeline expansion, supporting sustained growth.
- →Debt and cash: Net debt significantly reduced from INR 882 crore to INR 64 crore; INR 600 crore cash on hand supports financial health.
- →Product launches: ZAYNICH and Miqnaf expected to contribute significantly, with global addressable markets of USD 9 billion and INR 10,800 crores respectively.
- →Capacity expansion: Doubling manufacturing capacity in 24-36 months to meet growing demand.
- →Overall: Multiple growth levers in antibiotics, biotech, and biosimilars project solid earnings and profit growth over the next 3-5 years.
🏗️ Capital Expenditure Plans
- →Wockhardt is doubling its insulin and biotech manufacturing capacity over the next 24 to 36 months to meet growing demand and capitalize on emerging market opportunities.
- →The company is setting up a new facility for biotech products to support expansion in insulin analogs and related drugs.
- →Continued investment in R&D is planned, with an ongoing spend of around USD 200-250 million annually on new drug discovery and development, including antibiotics and biosimilars.
- →The company may consider further capital allocation for building in-house manufacturing capacity for ZAYNICH and other novel antibiotics as demand increases over the next 2-3 years.
- →Strategic investments include setting up a dedicated commercial organization for marketing ZAYNICH, possibly involving recruitment of senior management.
💰 Fundraising & Capital Structure
- →Wockhardt recently raised about INR 1,000 crores through equity (QIP) a few months ago.
- →The company is currently sitting on some cash and has improved EBITDA performance.
- →Management believes the current cash flow and funds raised will be more than adequate to support research and development.
- →They plan to continue spending approximately USD 200-250 million on new drug discovery annually.
- →There is no immediate plan indicated for further equity dilution or additional debt raising.
- →Overall, the company feels financially healthy and expects to meet future R&D and marketing requirements from existing resources.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Wockhardt Ltd Q4 FY25 results?
Wockhardt aims to double its business in the next 3 years, driven by increased capacity and growing demand, especially in novel antibiotics and biosimilars. EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%.
What is Wockhardt Ltd share price analysis?
Wockhardt Ltd currently shows a neutral. The stock trades at a P/E of 114.8 with a market cap of ₹32,598 Cr. Investors should review the full earnings analysis for detailed insights.
Is Wockhardt Ltd planning capital expenditure?
Wockhardt is doubling its insulin and biotech manufacturing capacity over the next 24 to 36 months to meet growing demand and capitalize on emerging market opportunities.
Keep Wockhardt Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.